Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rongsheng Jinbing 10%
- Development stage
- Unknown
- Lead developer
- Chengdu Rongsheng Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Rongsheng Jinbing 10% (蓉生静丙® 10%) is a fourth-generation plasma-derived intravenous immunoglobulin (IVIG) product developed by Chengdu Rongsheng Pharmaceuticals, a subsidiary of Beijing Tiantan Biological Products Co., Ltd (Tiantan Bio). Approved in China in 2023, it represents the first IVIG in the country manufactured using a three-step chromatographic purification process. This advanced technology results in higher purity and lower levels of impurities such as IgA and FXIa compared to traditional precipitation methods, thereby reducing the risk of allergic reactions and thrombosis. The product consists of pooled polyclonal antibodies derived from human plasma and works through immunoglobulin replacement and immunomodulatory mechanisms. It is indicated for the treatment of primary immunodeficiency disorders and various autoimmune diseases, including primary immune thrombocytopenia (ITP).
- Brand names
- 蓉生静丙Rongsheng Jinbing
- Other names
- Intravenous Immunoglobulin (pH4) 10%蓉生静丙 10%Rongsheng Jinbing 10%Human Immunoglobulin (pH4) for Intravenous Injection (10%)
02
Targets
FCGR1A (High affinity immunoglobulin gamma fc receptor I)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)FCGR2B (Fc gamma receptor IIB)Complement (Complement system)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on Rongsheng Jinbing 10%.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rongsheng Jinbing 10%.